Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exclusive Remicade Contracts Are Slowing Biosimilar Uptake

Executive Summary

Exclusive contracts for J&J's Remicade have posed challenges for Pfizer's Inflectra in the commercial insurance market, the biosimilar's maker said during its second quarter earnings call.

Advertisement

Related Content

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says
Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown
Biosimilar Humira Blocked Until 2023, But Time Could Clear Commercial Path
Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand
Pfizer Will Support Inflectra Launch With Dedicated Sales Force
Bundled Contracts To Defend Against Biosimilars May Face Payer Skepticism

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel